Werewolf Therapeutics, Inc.

Contributing Author

Recent Articles by Werewolf Therapeutics, Inc.

May-08	Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update HOWL GlobeNewswire
May-05	Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting HOWL GlobeNewswire
May-05	Werewolf Therapeutics to Participate in Upcoming Investor Conferences HOWL GlobeNewswire